GSK (NYSE:GSK) announced Monday that the U.S. Food and Drug Administration has accepted its priority review application for ...

GSK (NYSE:GSK) (LON:GSK) said on Monday that the U.S. Food and Drug Administration has accepted its priority review ...

Adams, who served as surgeon general during the first Trump administration, said Kennedy's assertions about the efficacy of ...

Robert F. Kennedy Jr., the health secretary and a longtime vaccine critic, announced in a statement Tuesday that $500 million ...

So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel ...

The federal government’s decision to slash $500 million in funding for mRNA vaccine research has sparked concern among health ...

An official overseeing implementation of the Make America Healthy Again agenda at the Department of Health and Human Services ...

GSK said it will receive $370 million as part of the U.S. patent settlement involving CureVac and BioNTech over mRNA-based COVID-19 vaccines, The Wall Street Journal reported Aug. 8. Under the deal, ...

Pima County health officials say fall vaccine supplies remain steady despite changes in federal research funding.

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...

CureVac and GSK will receive $740 million and single-digit royalties on COVID-19 vaccine sales in the U.S. going forward.